Eli Samaha Sells 25,027 Shares of Theravance Biopharma (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) major shareholder Eli Samaha sold 25,027 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $17.13, for a total value of $428,712.51. Following the completion of the transaction, the insider owned 9,212,252 shares in the company, valued at approximately $157,805,876.76. This trade represents a 0.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Eli Samaha also recently made the following trade(s):

• On Wednesday, July 1st, Eli Samaha sold 37,799 shares of Theravance Biopharma stock. The shares were sold at an average price of $17.00, for a total value of $642,583.00.
• On Monday, June 29th, Eli Samaha sold 273,871 shares of Theravance Biopharma stock. The stock was sold at an average price of $17.23, for a total transaction of $4,718,797.33.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH traded down $0.02 during mid-day trading on Wednesday, reaching $16.98. 1,319,960 shares of the company’s stock were exchanged, compared to its average volume of 689,283. Theravance Biopharma, Inc. has a 52-week low of $10.82 and a 52-week high of $21.03. The company’s 50-day moving average is $16.56 and its 200-day moving average is $17.29. The firm has a market capitalization of $875.32 million, a price-to-earnings ratio of 7.72 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. The business had revenue of $17.70 million during the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. As a group, equities analysts predict that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Weiss Ratings lowered shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 27th. Oppenheimer downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. B. Riley Financial raised their target price on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 7th. JonesTrading downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday. Finally, BTIG Research downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday. One investment analyst has rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $21.40.

Institutional Trading of Theravance Biopharma

Large investors have recently modified their holdings of the business. Quarry LP acquired a new position in shares of Theravance Biopharma during the 3rd quarter worth approximately $26,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Theravance Biopharma by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 515 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its position in Theravance Biopharma by 107.4% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,411 shares in the last quarter. CIBC Private Wealth Group LLC increased its position in Theravance Biopharma by 20,269.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 4,662 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 781 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.